Diagnosis and treatment of myocarditis
Article Sidebar
Main Article Content
Abstract
The recommendations are dedicated to contemporary aspects of epidemiology, etiology, pathogenesis, diagnosis, etiology-based, pathogenetic and symptomatic treatment of myocarditis. Various pathogenetic mechanisms that cause the development and progression of inflammatory heart disease and cause dilatation and systolic dysfunction, lead to heart failure and the development of other complications of myocarditis are described in detail. These recommendations present the modern classification of myocarditis, approved in Ukraine, and modern algorithms for diagnosis and clinical management of patients, in particular the algorithm that justifies the appointment of glucocorticoids for patients with myocarditis. The characteristics of different variants of myocarditis are also presented with clarifications concerning diagnosis and treatment. Much attention is paid to various approaches to the etiotropic and pathogenetic treatment of myocarditis and their possible prospects. It is obvious that in order to standardize approaches to the diagnosis and management of acute and chronic myocarditis, it is necessary to conduct large-scale multicenter studies and create special registries. In addition, in the current context of the COVID-19 pandemic, the pathological effects of SARS-Cov-2 as a trigger of myocarditis need further study, in particular in terms of impact on the prognosis and approaches to pathogenetic therapy in such patients. Unification of terminology and approaches to diagnosis and clinical monitoring of patients with myocarditis can improve management tactics and increase the survival rate of such patients. To identify high-risk patients (with arrhythmias, high probability of recurrence or transformation of myocarditis into dilated cardiomyopathy) and candidates for heart transplantation, the most promising is the creation of special databases of such patients
Article Details
Keywords:
References
Гавриленко Т.І., Чернюк С.В., Підгайна О.А. та ін. Визначення діагностичної і прогностичної ролі імунологічних біомаркерів у пацієнтів з міокардитом // Світ медицини та біології.– 2019.– № 2 (68).– C. 34–39. doi: 10.26724/2079-8334-2019-2-68-34-39.
Коваленко В.М., Лутай М.І., Сіренко Ю.М., Сичов О.С. Серцево-судинні захворювання: класифікація, стандарти діагностики та лікування.– К.: Моріон, 2020.– 239 с.
Коваленко В.М., Несукай О.Г., Чернюк С.В. та ін. Імуносупресивна терапія у хворих на міокардит: обґрунтування для використання в клінічній практиці // Укр. кардіол. журн.– 2019.– № 4.– С. 7–18.
Коваленко В.М., Несукай О.Г., Чернюк С.В. та ін. Лікування міокардиту: сучасні підходи та перспективні напрямки // Укр. кардіол. журн.– 2020.– № 6.– С. 61–70.
Коваленко В.М., Несукай О.Г., Чернюк С.В. та ін. Діагностика міокардиту як одна з актуальних проблем кардіології // Укр. кардіол. журн.– 2020.– № 4.– С. 78–89.
Коваленко В.М., Несукай О.Г., Тітова Н.С. та ін. COVID-19-асоційований міокардит: власний досвід патогенетичного лікування // Укр. кардіол. журн.– 2021.– № 3.– С. 7–17.
Чернюк С.В. Динамічні зміни структурно-функціонального стану серця у хворих на гострий міокардит // Запоріз. мед. журн.– 2019.– № 5 (21).– С. 576–581. doi: 10.14739/2310-1210.2019.5.179404.
Ammirati E., Frigerio M., Adler D.E. et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy // Circ. Heart Fail.– 2020.– Vol. 13.– P. e007405. doi: 10.1161/CIRCHEARTFAILURE.120.007405.
Ammirati E., Veronese G., Bottiroli M. et al. Update on acute myocarditis // Trends in Cardiovascular Medicine.– 2020. doi: 10.1016/j.tcm.2020.05.008.
Arnold J.R., McCann G.P. Cardiovascular Magnetic Resonance: Applications and Practical Considerations for the General Cardiologist // Heart.– 2020.– Vol. 106 (3).– P. 174–181. doi: 10.1136/heartjnl-2019-314856.
Aquaro G.D., Habtemicael G.Y., Camastra G. et al. Prognostic Value of Repeating Cardiac Magnetic Resonance in Patients With Acute Myocarditis // J. Am. Coll. Cardiol.– 2019.– Vol. 74 (20).– P. 2439–2448. doi: 10.1016/j.jacc.2019.08.1061.
Beling A., Kespohl M. Proteasomal protein degradation: adaptation of cellular proteolysis with impact on virus-and cytokine-mediated damage of heart tissue during myocarditis // Front Immunol.– 2018.– Vol. 9.– P. 2620. doi: 10.3389/fimmu.2018.02620.
Bettencourt N. Cardiac magnetic resonance in myocarditis – do we need more tools? // Rev. Port. Cardiol.– 2019.– Vol. 38 (11).– P. 777–778. doi: 10.1016/j.repc.2020.01.002.
Błyszczuk P. Myocarditis in humans and in experimental animal models // Front Cardiovasc. Med.– 2019.– Vol. 6.– P. 64. doi: 10.3389/fcvm.2019.00064.
Blauwet L.A., Cooper L.T. Myocarditis // Prog. Cardiovasc. Dis.– 2016.– Vol. 52 (4).– P. 274–288. doi: 10.1016/j.pcad.2009.11.006.
Caforio A.L.P., Adler Y., Agostini C. et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease // Eur. Heart J.– 2017.– Vol. 38 (35).– P. 2649–2662. doi: 10.1093/eurheartj/ehx321.
Caforio A.L., Malipiero G., Marcolongo R., Iliceto S. Myocarditis: a clinical overview // Curr. Cardiol. Rep.– 2017.– Vol. 19 (7).– P. 63. doi: 10.1007/s11886-017-0870-x.
Caforio A.L., Pankuweit S., Arbustini E. et al. Current state of knowledge on aetiology, diagnosis, management and therapy of myocarditis: a position statement of the ESC Working group on myocardial and pericardial diseases // Eur. Heart J.– 2013.– Vol. 34 (33).– P. 2636–2648. doi: 10.1093/eurheartj/eht210.
Cecco C.N.D., Monti C.B. Use of Early T1 Mapping for MRI in Acute Myocarditis // Radiology.– 2020.– Vol. 295 (2).– P. 326–327. doi: 10.1148/radiol.2020200171.
Chen W., Jeudy J. Assessment of Myocarditis: Cardiac MR, PET/CT, or PET/MR? // Curr. Cardiol. Rep.– 2019.– Vol. 21 (8).– P. 76. doi: 10.1007/s11886-019-1158-0.
Chen G., Li H., Hang W., Wang D.W. Cardiac injuries in coronavirus disease 2019 (COVID-19) // J. Mol. Cell. Cardiol.– 2020.– Vol. 145.–P. 25–29. doi: 10.1016/j.yjmcc.2020.06.002.
Chimenti C., Verardo R., Scopelliti F. et al. Myocardial expression of Toll-like receptor 4 predicts the response to immunosuppressive therapy in patients with virus-negative chronic inflammatory cardiomyopathy // Eur. J. Heart Fail.– 2017.– Vol. 19 (7).– P. 915–925. doi: 10.1002/ejhf.796.
Corsten M., Heggermont W., Papageorgiou A.P. et al. The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis // Eur. Heart J.– 2015.– Vol. 36.– P. 909–919. doi: 10.1093/eurheartj/ehv321.
Ebert M., Richter S., Dinov B. et al. Evaluation and management of ventricular tachycardia in patients with dilated cardiomyopathy // Heart Rhythm.– 2019.– Vol. 16 (4).– P. 624–631. doi: 10.1016/j.hrthm.2018.10.028.
Eichhorn C., Bière L., Schnell F. et al. Myocarditis in Athletes Is a Challenge: Diagnosis, Risk Stratification, and Uncertainties // JACC Cardiovasc Imaging.– 2019.– Vol. 13.– P. 494–507. doi: 10.1016/j.jcmg.2019.01.039.
Escher F., Kühl U., Lassner D. et al. Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. // Clin. Res. Cardiol.– 2016.– Vol. 105.– P. 1011–1020. doi: 10.1007/s00392-016-1011-z.
Fairweather D., Cooper L.T., Blauwet L.A. Sex and gender differences in myocarditis and dilated cardiomyopathy // Curr. Probl. Cardiol.– 2013.– Vol. 38 (1).– P. 7–46. doi: 10.1016/j.cpcardiol.2012.07.003.
Ferreira V.M., Schulz-Menger J., Holmvang G. et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations // J. Am. Coll. Cardiol.– 2018.– Vol. 72 (24).– P. 3158–3176. doi: 10.1016/j.jacc.2018.09.072.
Friedrich M.G., Sechtem U., Schulz-Menger J. et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper // J. Am. Coll. Cardiol.– 2009.– Vol. 53 (17).– P. 1475–1487. doi: 10.1016/j.jacc.2009.02.007.
Frustaci A., Chimenti C. Immunosupressive therapy in myocarditis // Circulation J.– 2014.– Vol. 79.– P. 4–7. doi: 10.1253/circj.CJ-14-1192.
Fung G., Luo H., Qiu Y. et al. Myocarditis // Circ. Res.– 2016.– Vol. 118 (3).– P. 496–514. doi: 10.1161/CIRCRESAHA.115.306573.
Hase H., Saito T., Yamazaki H. et al. Successful treatment using corticosteroids in early phase of eosinophilic myocarditis with eosinophilic granulomatosis with polyangiitis // J. Cardiology Cases.– 2016.– Vol. 14 (6).– P. 177–180. doi: 10.1016/j.jccase.2016.08.006.
He J., Yang L. Value of three-dimensional speckle-tracking imaging in detecting left ventricular systolic function in patients with dilated cardiomyopathy // Echocardiography.– 2019.– Vol. 36 (8).– P. 1492–1495. doi: 10.1111/echo.14427.
Hendry R.G., Bilawchuk L.M., Marchant D.J. Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis // J. Cardiovasc. Transl. Res.– 2014.– Vol. 7 (2).– P. 212–215. doi: 10.1007/s12265-013-9528-2.
Heymans S., Corsten M.F., Verhesen W. et al. Macrophage microRNA-155 promotes cardiac hypertrophy and failure // Circulation.– 2013.– Vol. 128.– P. 1420–1432.
doi: 10.1161/CIRCULATIONAHA.112.001357.
Heymans S., Eriksson U., Lehtonen J., Cooper T.L. The quest for new approaches in myocarditis and inflammatory cardiomyopathy // J. Am. Coll. Cardiol.– 2016.– Vol. 68 (21).– P. 2348–2364. doi: 10.1016/j.jacc.2016.09.937.
Hu J.R., Florido R., Lipson E.J. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors // Cardiovasc. Res.– 2019.– Vol. 115.– P. 854–868. doi: 10.1093/cvr/cvz026.
Hua X., Song J. Immune cell diversity contributes to the pathogenesis of myocarditis // Heart Fail. Rev.– 2019.– Vol. 24 (6).– P. 1019–1030. doi: 10.1007/s10741-019-09799-w.
Huber S.A. Viral myocarditis and dilated cardiomyopathy: etiology and pathogenesis // Curr. Pharm. Des.– 2016.– Vol. 22 (4).– P. 408–426. doi: 10.2174/1381612822666151222160500.
Imanaka-Yoshida K. Inflammation in myocardial disease: From myocarditis to dilated cardiomyopathy // Pathology International.– 2020.– Vol. 1.– P. 1–11 doi: 10.1111/pin.12868.
Kasner M., Sinning D., Escher F. et al. The utility of speckle tracking imaging in the diagnostic of acute myocarditis, as proven by endomyocardial biopsy // Int. J. Cardiol.–
– Vol. 168 (3).– P. 3023–3024. doi: 10.1016/j.ijcard.2013.04.016.
Kim M.J., Hong G.R., Ha J.W., Shim C.Y. Acute Localized Myocarditis: Role of Speckle Tracking Echocardiography // Korean Circ J.– 2020.– Vol. 50 (7).– P. 638–640. doi: 10.4070/kcj.2019.0378.
Kociol R.D., Cooper L.T., Fang J.C. et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association // Circulation.– 2020.– Vol. 141 (6).– P. e69–e92. doi: 10.1161/CIR.0000000000000745.
Kovalenko V., Nesukay E., Cherniuk S. et al. Role of myocardial inflammation and fibrosis in the development of ventricular arrythmias in patients with inflammatory cardiomyopathy (results of 1-year follow-up) // Eur. Heart J.– Vol. 41
(Suppl. 2).– ESC Congress 2020. Abstract Supplement.– P. 2054. doi: 10.1093/ehjci/ehaa946.2054.
Krejci J., Mlejnek D., Sochorova D., Nemec P. Inflammatory cardiomyopathy: a current view on pathophysiology, diagnosis and treatment // BioMed Research International.– 2016.– P. 1–11. doi: 10.1155/2016/4087632.
Kuhl U., Lassner D., Gast M. et al. Differential cardiac microRNA expression predicts the clinical course in human enterovirus cardiomyopathy // Circ. Heart Fail.– 2015.– Vol. 8.– P. 605–618. doi: 10.1161/CIRCHEARTFAILURE.114.001475.
Kuruvilla S., Adenaw N., Katwal A.B. et al. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis // Circ. Cardiovasc. Imaging.– 2014.– Vol. 7 (2).– P. 250–258. doi: 10.1161/CIRCIMAGING.113.001144.
Leone O., Pieroni M., Rapezzi C., Olivotto I. The spectrum of myocarditis: from pathology to the clinics // Virchows Arch.– 2019.– Vol. 475 (3).– P. 279–301. doi: 10.1007/s00428-019-02615-8.
Lu C., Qin F., Yan Y., Liu T. et al. Immunosupressive treatment for myocarditis: a meta-analysis of randomized controlled trials // J. Cardiovasc. Med.– 2017.– Vol. 17.– P. 631–637. doi: 10.2459/jcm.0000000000000134.
Lu M., Samblanet K., Roberts C. Myocarditis: A Heart on Fire // Curr. Sports Med. Rep.– 2020.– Vol. 19 (3).– P. 110–112. doi: 10.1249/JSR.0000000000000698.
Mahrholdt H., Greuilich S. Prognosis in myocarditis // J. Am. Col. Cardiol.– 2017.– Vol. 70.– P. 1988–1990. doi: 10.1016/j.jacc.2017.08.062.
Maisch B. Cardio-Immunology of myocarditis: focus on immune mechanisms and treatment options // Frontiers in Cardiovascular Medicine.– 2019.– Vol. 6.– P. 48. doi: 10.3389/fcvm.2019.00048.
Maisch B., Alter P. Treatment options in myocarditis and inflammatory cardiomyopathy: focus on i. v. immunoglobulins // Herz.– 2018.– Vol. 43 (5).– P. 423–430. doi: 10.1007/s00059-018-4719-x.
Maisch B., Ristic A.D., Pankuweit S. Inflammatory cardiomyopathy and myocarditis // Herz.– 2017.– Vol. 42 (4).– P. 425–438. doi: 10.1007/s00059-017-4569-y.
Massilamany C., Huber S.A., Cunningham M.W., Reddy J. Relevance of molecular mimicry in the mediation of infectious myocarditis // J. Cardiovasc. Trans. Res.– 2014.– Vol. 7 (2).– P. 165–171. doi: 10.1007/s12265-013-9519-3.
Merken J., Hazebroek M., Van Paassen P. et al. Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus Negative Nonfulminant Inflammatory Cardiomyopathy // Circulation: Heart Failure.– 2018.– Vol. 11.– P. e004228. doi: 10.1161/ CIRCHEARTFAILURE.117.004228.
Nensa F., Kloth J., Tezgah E. et al. Feasibility of FDG-PET in myocarditis: Comparison to CMR using integrated PET/MRI // J. Nucl. Cardiol.– 2016.– Vol. 25.– P. 616–624. doi: 10.1007/s12350-016-0616-y.
Ozieranski K., Tyminska A., Jonik S. et al. Clinically Suspected Myocarditis in the Course of Severe Acute Respiratory Syndrome Novel Coronavirus-2 Infection: Fact or Fiction? // J. Card. Fail.– 2021.– Vol. 27 (1).– P. 92–96. doi: 10.1016/j.cardfail.2020.11.002.
Palmisano A., Benedetti G., Faletti R. et al. Early T1 Myocardial MRI mapping: value in detecting myocardial hyperemia in acute myocarditis // Radiology.– 2020.– Vol. 295 (2).– Р. 316–325. doi: 10.1148/radiol.2020191623.
Peretto G., Sala S., Rizzo S. et al. Arrhythmias in myocarditis: state of the art // Heart Rhythm Case Reports.– 2019.– Vol. 16 (5).– P. 793–801. doi: https://doi.org/10.1016/j.hrthm.2018.11.024.
Pinto Y.M., Elliott P.M., Arbustini E. et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases // Eur. Heart J.– 2016.– Vol. 37 (23).– P. 1850–1858. doi: 10.1093/eurheartj/ehv727.
Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // Eur. Heart J.– 2016.– Vol. 37.– P. 2129–2200. doi: 10.1093/eurheartj/ehw128.
Qin F., Yan Y., Liu T., Li J., Chen H. Immunosuppressive treatment for myocarditis: a meta-analysis of randomized controlled trials // J. Cardiovasc. Med. Hagerstown.– 2016.– Vol. 17 (8).– P. 631–637. doi: 10.2459/JCM.0000000000000134.
Robinson J., Hartling L., Vandermeer B., Klassen T.P. Intravenous immunoglobulin for presumed viral myocarditis in children and adults // Cochrane Database Syst. Rev.– 2015.– Vol. 20 (5).– P. CD004370. doi: 10.1002/14651858.CD00437.
Rose N.R. Critical cytokine pathways to cardiac inflammation // J. Interferon Cytok. Res.– 2011.– Vol. 31.– P. 705–709. doi: 10.1089/jir.2011.0057.
Rutschow S., Leschka S., Westermann D. et al. Left ventricular enlargement in coxsakievirus-B3 induced myocarditis ongoing inflammation and an imbalance of the matrix degrading system // Eur. Pharmacol.– 2010.– Vol. 630.– P. 145–151. doi: 10.1016/j.ejphar.2009.12.019.
Sakibuzzaman M., Fariza T.T., Rahman S.M. et al. A Clinical Review of COVID-19 Associated Myocarditis // Archives of Clinical and Biomedical Research.– 2020.– Vol. 4 (5).– P. 468–480. doi: 10.26502/acbr.50170119.
Sawalha K., Abozenah M., Kadado A.J. et al. Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome // Cardiovasc. Revasc. Med.– 2021.– Vol. 23.– P. 107–113. doi: 10.1016/j.carrev.2020.08.028.
Schultheiss H.P., Escher F. Chapter Tratment of myocarditis in ESC CardioMed / Eds. A.J. Camm, T.F. Luscher, G. Maurer, P.W. Serruys.– Oxford University Press, 2018. doi: 10.1093/med/9780198784906.003.0368.
Schultheiss H.P., Piper C., Sowade O. et al. Betaferon in chronic viral cardiomyopathy (BICC) trial: effects ofinterferon-b treatment in patients with chronic viral cardiomyopathy // Clin. Res. Cardiol.– 2016.– Vol. 105.– P. 763–769. doi: 10.1007/s00392-016-0986-9.
Seferovic P.M., Polovina M., Bauersachs J. et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology // Eur. J. Heart Failure.– 2019.– Vol. 21.– P. 553–576. doi: 10.1002/ejhf.1461.
Shah Z., Mohammed M., Vuddanda V. et al. National trends, gender, management, and outcomes of patients hospitalized for myocarditis // Am. J. Cardiol.– 2019.– Vol. 124 (1).– P. 131–136. doi: 10.1016/j.amjcard.2019.03.036.
Sinagra G.F., Anzini M., Pereira N.L. et al. Myocarditis in clinical practice // Mayo Clin. Proc.– 2016.– Vol. 91 (9).– P. 1256–1266. doi: 10.1016/j.mayocp.2016.05.013.
Siripanhong B., Nazarian S., Muser D. et al. Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management // Heart Rhythm.– 2020.– Vol. 17 (9).– P. 1463–1471. doi: 10.1016/j.hrthm.2020.05.001.
Swirski F.K., Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease // Nat. Rev. Immunol.– 2018.– Vol. 18.– P. 733–744. doi: 10.1038/s41577-018-0065-8.
Tong R., Jia T., Shi R. Yan F. Inhibition of microRNA-155 protects H9c2 cells against CVB3-induced myocardial injury by targeting NLRX1 to regulate the NLRP3 inflammasome // Cellular & Molecular Biology Letters.– 2020.– Vol. 25 (6). doi: 10.1186/s11658-020-00203-2.
Treibel T.A., Fridman Y., Bering P. et al. Extracellular Volume Associates With Outcomes More Strongly Than Native or Post-Contrast Myocardial T1 // JACC: Cardiovascular Imaging.– 2020.– Vol. 13 (1).– P. 44–54. doi: 10.1016/j.jcmg.2019.03.017.
Tschöpe C., Ammirati E., Bozkurt B. et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions // Nat. Rev. Cardiol.– 2021.– Vol. 18 (3).– P. 169–193. doi: 10.1038/s41569-020-00435-x.
Tschöpe C., Cooper L.T., Torre-Amione G., Van Linthout S. Management of myocarditis-related cardiomyopathy in adults // Circ. Res.– 2019.– Vol. 124 (11).– P. 1568–1583. doi: 10.1161/CIRCRESAHA.118.313578.
Van Den Hoogen P., Van Den Akker F., Deddens J.C., Sluijter J.P. Heart failure in chronic myocarditis: a role for microRNAs? // Curr. Genomics.– 2015.– Vol. 16 (2).– P. 88–94. doi: 10.2174/1389202916999150120153344.
Van Linthout S., Klingel K., Tschope C. SARS-CoV2-related myocarditis-like syndroms: Shakespeare’s question: What’s in a name? // Eur. J. Heart Fail.– 2020.– Vol. 22.– P. 922–925. doi: 10.1002/ejhf.1899.
Van Linthout S., Tschöpe C. Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy // Curr. Opin. Cardiol.– 2018.– Vol. 33 (3).– P. 325–333. doi: 10.1097/HCO.0000000000000515.
Yan L., Hu F., Yan X. et al. Inhibition of microRNA-155 ameliorates experimental autoimmune myocarditis by modulating Th17/Treg immune response // J. Mol. Med. (Berl).– 2016.– Vol. 94.– P. 1063–1079. doi: 10.1007/s00109-016-1414-3.
Yang Y., Lv J., Jiang S. et al. The emerging role of Toll-like receptor 4 in myocardial inflammation // Cell Death and Disease.– 2016.– Vol. 7.– P. e2234. doi: 10.1038/cddis.2016.140.
Zanatta A., Carturan E., Rizzo S. et al. Story telling of myocarditis // Int. J. Cardiol.– 2019.– Vol. 294.– P. 61–64. doi: 10.1016/j.ijcard.2019.07.046.